No abstract

On August 27, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents (1). Nearly one third of adolescents aged 12-17 years hospitalized with during March 2020-April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation (2). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 16-17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12-15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the United States, CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series † among adolescents aged 12-17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020-July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12-17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% * Receipt of ≥1 COVID-19 vaccine dose is defined as having received either ≥1 of the 2 Pfizer-BioNTech or Moderna vaccine doses, or a single dose of the Janssen (Johnson & Johnson) vaccine. As of August 17, 2021, only the Pfizer-BioNTech vaccine had been authorized for use among adolescents aged 12-17 years. Moderna and Janssen COVID-19 vaccines were not authorized under emergency use for this age group during December 14, 2020-July 31, 2021. However, doses of these vaccines administered to persons aged 12-17 years were included in this analysis. During February 27, 2021-July 31, 2021, a total of 21,919 adolescents aged 12-17 years were reported to have received 1 dose of the Janssen COVID-19 vaccine. During December 14, 2021-July 31, 2021, a total of 27,226 adolescents aged 12-17 years were reported to have received only the first dose of the Moderna COVID-19 vaccine; 66,032 adolescents aged 12-17 years were reported to have received both doses of the Moderna 2,190 were reported to have received Pfizer-BioNTech for the first dose but Moderna for the second dose; and 5,726 were reported to receive Moderna for the first dose but Pfizer-BioNTech for the second dose. † Series completion was defined as receipt of either both doses of the Pfizer-BioNTech or Moderna vaccines, including those that might have received mismatched products between the first and second dose (i.e., Pfizer-BioNTech for the first dose and Moderna for the second dose or vice versa) or a single dose of the Janssen vaccine.[Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 year...

A lthough more common among adults, severe coronavirus disease (COVID-19) and hospitalization can occur in children. Among >8,300 hospitalized children 5-11 years of age, 1/3 required intensive care (1,2). Children can transmit severe acute respiratory syndrome coronavirus 2 to others, highlighting the need for pediatric COVID-19 vaccinations. On November 2, 2021, the US Centers for Disease Control and Prevention (CDC) recommended the use of the Pfizer-BioNTech COVID-19 vaccine (Pfizer Inc., https://www.pfizer.com) in children 5-11 years of age. We analyzed first-dose vaccination coverage among children 5-11 years of age and stratified coverage by age group, sex, race/ ethnicity, and jurisdiction. The StudyWe analyzed COVID-19 vaccine administration data among children 5-11 years of age in the United States during November 2-December 31, 2021. We collected data that were reported to CDC from jurisdictions, pharmacies, and federal entities through immunization information systems, the Vaccine Administration Management System, and direct data submission by January 21, 2022 (Appendix, https://wwwnc.cdc. gov/EID/article/28/5/22-0166.pdf). We calculated daily and cumulative total numbers of children receiving the first dose of Pfizer-BioNTech COVID-19 vaccine. We calculated vaccination coverage by dividing the number of children who received the first vaccine dose by the total population of children in the corresponding age group living in the defined jurisdiction. We stratified vaccine coverage by jurisdiction, age group (5-6, 7-8, and 9-11 years), and sex. We obtained the population size for children 5-11 years of age from the US Census Bureau 2020 Population Estimates (3). Among 82.1% of children 5-11 years of age for whom race and ethnicity data were available, we calculated the percentage of children receiving their first COVID-19 vaccine dose by race/ ethnicity and compared this with the racial and ethnic makeup of the US population 5-11 years of age.We did not conduct tests for statistical significance because these data reflect US population and not population samples. We used SAS version 9.4 (SAS Institute, Inc., https://www.sas.com) to perform analyses. This study was reviewed by CDC and conducted consistent with applicable federal law and CDC policy.

No abstract

No abstract